Yaron Werber
Stock Analyst at TD Cowen
(0.88)
# 3,573
Out of 4,831 analysts
43
Total ratings
31.03%
Success rate
-20.53%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Yaron Werber
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SWTX SpringWorks Therapeutics | Downgrades: Hold | $66 → $47 | $46.22 | +1.69% | 1 | Apr 29, 2025 | |
| ONC BeiGene | Reiterates: Buy | $334 | $224.73 | +48.62% | 1 | Apr 24, 2025 | |
| FBRX Forte Biosciences | Initiates: Buy | n/a | $6.80 | - | 1 | Jan 21, 2025 | |
| DNTH Dianthus Therapeutics | Initiates: Buy | n/a | $18.84 | - | 1 | Dec 20, 2024 | |
| SEPN Septerna | Initiates: Buy | n/a | $6.73 | - | 1 | Nov 19, 2024 | |
| ASND Ascendis Pharma | Maintains: Buy | $160 → $153 | $161.52 | -5.27% | 5 | Nov 15, 2024 | |
| BNTX BioNTech SE | Maintains: Hold | $132 → $122 | $94.50 | +29.10% | 5 | Nov 6, 2024 | |
| UPB Upstream Bio | Initiates: Buy | n/a | $8.65 | - | 1 | Nov 5, 2024 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Buy | $61 → $73 | $35.40 | +106.21% | 2 | Oct 21, 2024 | |
| EXEL Exelixis | Maintains: Buy | $27 → $34 | $36.95 | -7.98% | 2 | Oct 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $54 → $59 | $32.53 | +81.37% | 1 | Jul 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $71 → $67 | $31.08 | +115.57% | 2 | Jul 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $8.93 | - | 1 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $4.82 | - | 1 | Mar 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.28 | - | 2 | Mar 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $5.00 | - | 2 | Jan 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $19.63 | - | 1 | Dec 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $612 → $641 | $542.47 | +18.16% | 3 | Dec 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $0.39 | - | 1 | Oct 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $15 → $25 | $0.30 | +8,252.82% | 1 | Feb 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $12.74 | - | 2 | Nov 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $38 | $19.31 | +96.79% | 1 | May 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $3.31 | - | 3 | Apr 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $1.00 | - | 1 | Nov 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $10.76 | - | 1 | Oct 26, 2021 |
SpringWorks Therapeutics
Apr 29, 2025
Downgrades: Hold
Price Target: $66 → $47
Current: $46.22
Upside: +1.69%
BeiGene
Apr 24, 2025
Reiterates: Buy
Price Target: $334
Current: $224.73
Upside: +48.62%
Forte Biosciences
Jan 21, 2025
Initiates: Buy
Price Target: n/a
Current: $6.80
Upside: -
Dianthus Therapeutics
Dec 20, 2024
Initiates: Buy
Price Target: n/a
Current: $18.84
Upside: -
Septerna
Nov 19, 2024
Initiates: Buy
Price Target: n/a
Current: $6.73
Upside: -
Ascendis Pharma
Nov 15, 2024
Maintains: Buy
Price Target: $160 → $153
Current: $161.52
Upside: -5.27%
BioNTech SE
Nov 6, 2024
Maintains: Hold
Price Target: $132 → $122
Current: $94.50
Upside: +29.10%
Upstream Bio
Nov 5, 2024
Initiates: Buy
Price Target: n/a
Current: $8.65
Upside: -
Ultragenyx Pharmaceutical
Oct 21, 2024
Maintains: Buy
Price Target: $61 → $73
Current: $35.40
Upside: +106.21%
Exelixis
Oct 21, 2024
Maintains: Buy
Price Target: $27 → $34
Current: $36.95
Upside: -7.98%
Jul 23, 2024
Maintains: Buy
Price Target: $54 → $59
Current: $32.53
Upside: +81.37%
Jul 15, 2024
Maintains: Buy
Price Target: $71 → $67
Current: $31.08
Upside: +115.57%
Mar 26, 2024
Upgrades: Buy
Price Target: n/a
Current: $8.93
Upside: -
Mar 18, 2024
Initiates: Outperform
Price Target: n/a
Current: $4.82
Upside: -
Mar 15, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $1.28
Upside: -
Jan 31, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $5.00
Upside: -
Dec 20, 2023
Initiates: Outperform
Price Target: n/a
Current: $19.63
Upside: -
Dec 12, 2023
Maintains: Outperform
Price Target: $612 → $641
Current: $542.47
Upside: +18.16%
Oct 19, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $0.39
Upside: -
Feb 28, 2023
Maintains: Market Perform
Price Target: $15 → $25
Current: $0.30
Upside: +8,252.82%
Nov 1, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $12.74
Upside: -
May 2, 2022
Initiates: Market Perform
Price Target: $38
Current: $19.31
Upside: +96.79%
Apr 6, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $3.31
Upside: -
Nov 30, 2021
Initiates: Outperform
Price Target: n/a
Current: $1.00
Upside: -
Oct 26, 2021
Initiates: Outperform
Price Target: n/a
Current: $10.76
Upside: -